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INTRODUCTION 
Gene transfer offers the potential to analyze the effects of recombinant genes 
in cells and organisms. Most applications of gene transfer are performed on cells 
in vim. Recently, however, recombinant genes have been introduced directly 
into tissues in vivo. In this laboratory, viral and nonviral vectors have been 
introduced through intraarterial catheters to achieve recombinant gene expres- 
sion in localized segments of blood vessels. The effects on arteries induced by 
localized expression of several genes with mitogenic and angiogenic effects have 
been analyzed in v b o .  Through intravascular gene transfer, genes involved in the 
pathogenesis of atherosclerosis are being defined in clinically relevant animal 
models of disease. Identification of genes that can regulate proliferation of vas- 
cular cells and alter their thrombogenicity in vivo may provide gene-based strat- 
egies to ameliorate this disease. 
Cancer cells are derived from normal precursors, which undergo a series of 
genetic alterations in successive clones of cells, resulting in uncontrolled pro- 
liferation and metastasis. Abnormal gene products synthesized by neoplastic cells 
can potentially generate novel tumor antigens. Appropriate stimulation of the 
immune system can induce a cell-mediated immune response directed against 
tumor antigens, and the transfer of inmunostimulatory genes into nonimmun- 
ogenic tumor cells can stimulate antitumor responses in animals that are pro- 
tective against the nontransduced tumor cells upon rechallenge. We utilized 
direct gene transfer to introduce an allogeneic class I major histocompatibility 
complex (MHC) gene into tumors in v b o .  Expression of this recombinant gene 
within tumors stimulated a cell-mediated antitumor immune response. Unlike 
#Address for correspondence: Dr. Gregory E. Plaua, Department of Pediatrics and 
Communicable Diseases, University of Michigan Medical Center, MSRB I Room A5 10, 
1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0684. 
144 
PLAUTZ et a/.: DIRECT GENE TRANSFER 145 
transduction of tumor cells in p i ~ o ,  and subsequent inoculation into a non- 
tumor-bearing host, direct gene transfer allows modifications of established 
tumors. Thus, strategies to augment the immune response to preexisting tumors 
can be evaluated, providing a more realistic model for clinical applications in 
human malignancies. 
In this paper, we review the application of direct gene transfer to the study 
of vascular biology and its use for provision of immunotherapy in malignancy. 
Direct gene transfer with DNA liposome complex is less costly and time con- 
suming than cell-mediated gene transfer. Moreover, the stability of liposome and 
DNA preparations and the ease with which they can be prepared and admin- 
istered to recipients could facilitate their use in clinical therapy. 
METHODS OF DIRECT GENE DELIVERY 
Direct gene transfer is a useful method to modify endogenous cells in vivo to 
study the effects of recombinant gene expression. Several methods of gene 
transfer in vivo have been demonstrated. Viral vectors, including retrovirus- 
es, I-3adenoviruses,M adeno-associated viruses,’ and herpes virusess-l0 have been 
modified to express recombinant genes and eliminate their ability to replicate. 
Direct injection of DNA into certain cell types such as skeletal or cardiac myo- 
cytes and melanoma has allowed expression of recombinant genes. DNA 
forms a complex with cationic liposomes that improves the efficiency of recom- 
binant gene transfer into cells in p i v ~ . ~ J ~ - ’ ~  
Cationic liposomes exhibit features that significantly improve their efficacy 
for in pivo gene transfer. They can be prepared in large batches by sonication to 
form particles of approximately 250-nm diameter that are stable in aqueous 
solution for months. Through an electrostatic interaction, the lipids condense 
with the DNA to efficiently encase it. Liposomes interact with the cell surface, 
allowing the DNA to traverse the plasma membrane of target cells. The DNA 
is subsequently transferred to the nucleus to direct transcription through in- 
completely defined mechanisms.20 Cationic liposomes can be signficantly in- 
activated by Therefore, transduction of cells is most effective at the site 
of delivery. Two cationic liposome preparations have been used in this laboratory 
for site-specific gene transfer. Lipofectin” (Bethesda Research Laboratories, Gai- 
thersburg, MD), a mixture of DOTMA (N-[2,3-dioleyloxy)propyl]-N,N,N- 
trimethylammonium chloride) and DOPE (dioleoyl phosphatidylethanola- 
mine),22 has been used to deliver recombinant genes into vascular cells in 
~ e r i p h e r a l ~ . ~ ~  and coronary24 arteries in PiPo. Another cationic liposome prepara- 
tion, containing DC-cholesterol (3P[N-(N’N’-dimethylaminoethane)-carba- 
moyl] cholesterol) and has also provided efficient gene transduction of 
vascular cells and malignant tumor~l~ in PiPo. 
Several features of liposome-mediated gene transfer facilitate its application 
to direct gene transfer in PiPo. In contrast to retrovirus-mediated gene transfer, 
replication of the recipient cell is not necessary. Therefore, terminally differ- 
entiated somatic cells can serve as targets. Also, unlike viral vectors, there are few 
constraints on vector size or transcriptional signals, and a variety of tissue-specific 
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enhancer/promoter elements or polycistronic vectors may be used. DNA lipo- 
some complexes form rapidly in aqueous solution without extensive preparation, 
permitting rapid analysis of a series of vectors for activity in pitro or in pipg. The 
DC-cholesterol preparation is nontoxic over a wide range of concentrations in 
pitm and is metabold  in PiPo.25 Extensive toxicity testing has demonstrated the 
DC-cholesterol liposome preparation to be safe in PiPo. 26327$4 
SITE-SPECIFIC GENE TRANSFER INTO 
VASCULAR CELLS IN W O  
To introduce recombinant genes into specific target tissues in vim, we deliv- 
ered retroviral vectors or DNA lipomme complexes to anatomically localized 
sites. Initially, vascular cells were transduced with recombinant genes in pipg, 
using retroviral vectors or DNA liposome complexes instilled into localized 
arterial segments. In a porcine model, a segment of the iliofemoral artery was 
isolated from the systemic circulation using a double balloon catheter. The space 
between the two balloons was flushed to remove residual serum, and a con- 
centrated suspension of amphotropic Moloney murine leukemia viral vector or 
DNA liposome complexes was instilled in the arterial segment for thirty minutes 
prior to removal of the catheter. Recombinant gene expression was present in 
endothelial cells, vascular smooth muscle cells, and adventitial cells in arteries 
transduced with the marker gene fl-galactosidase. Recombinant gene expression 
decreased with time but was clearly present up to 21 weeks following retroviral 
gene transfer and was not detected in the downstream arterial segment or in 
other tissues by PCR analy~is.~ 
Intraarterial direct gene transfer can elucidare the pathologic response to 
recombinant growth factor gene expression in normal and injured arteries. The 
endothelial cell growth factor fibroblast growth factor-1 (FGF-1) induces en- 
dothelial cell proliferation in Pitm and is angiogenic in *. Because FGF-1 lacks 
a classical signal sequence, the study of its effects as an extracellular protein has 
been difficult. A chimeric gene, in which the signal sequence from the FGF-4 
gene was fused to the coding sequence of FGF-1, was introduced directly into 
l o c a l i i  segments of arteries in vim. This plasmid, complexed with Lipofectin@, 
was transfected into porcine arteries at low instillation pressure (150 mmHg) to 
minimize trauma to the vessel. Presence of the introduced DNA was confirmed 
21 days after transfection by PCR, and protein expression was confirmed by 
immunohistochemisay. The secreted FGF- 1 gene induced intimal proliferation, 
and in several vessels capillary formation was observed in the neointima.'* Such 
angiogenesis has been observed in atherosclerotic plaques; however, mecha- 
nisms to explain this observation have previously been lacking. Because of its 
effects as an angiogenic factor, this FGF-1 vector could potentially be useful to 
induce neovascularization of ischemic tissue following intravascular delivery into 
affected tissue. 
Platelet-derived growth factor (PDGF) B chain has also been implicated in 
the generation of atherosclerosis. This growth factor is a potent mitogen for 
vascular smooth muscle cells, but does not induce proliferation of endothelial 
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cells. To analyze the response to this growth factor in vivo, a plasmid expression 
vector encoding the human PDGF B gene was introduced into porcine arteries 
using Lipofectin@ at low instillation pressures.19 The expression of introduced 
DNA was confirmed by PCR analysis of recombinant PDGF B mRNA. Im- 
munohistochemistry revealed human PDGF BB protein expression in the intima 
and media but not in control arteries transduced with P-galactosidase. Quanti- 
tative morphometry of intimal and medial thickness demonstrated a sevenfold 
increase in the intimal-to-medical ratio compared to p-galactaidax-transduced 
vessels. Unlike the FGF-1-transduced arteries, the intimal thickening was not 
associated with neocapillary formation. These studies provide a method to ex- 
amine the effects of recombinant growth factor gene expression on vascular 
physiology in normal and injured arteries. Such studies also provide a model to 
investigate inhibition of intimal proliferation using gowth factor or receptor 
antagonists. 
To analyze the response of the immune system to a foreign protein expressed 
on endogenous vascular cells, a human MHC gene, HLA-B7, was introduced 
into the iliofemoral artery of pigs using retroviral vectors or  DNA liposome 
complexes.23 Both vectors provided expression of HLA-B7 protein within vas- 
cular cells documented by PCR analysis of DNA and mRNA and by immun- 
ohistochemistry. Expression of the foreign histocompatibility antigen by vascu- 
lar cells induced an intense inflammatory response in recipient animals, 
consisting of a mononuclear cell infiltrate in the adventitia and media. The 
inflammatory response was present by 1 1 days after gene transfer, peaked at 17 
to 21 days, and had subsided by 75 days. Some neointimal thickening, as is seen 
following chronic inflammation, was noted in the transduced arteries. Further 
studies determined that cytotoxic T lymphocytes specific for the foreign antigen 
were generated in these animals. Control arteries transduced with the p-galacto- 
sidase gene did not develop inflammatory histologic changes or an immune 
response. The histologic and immunologic responses induced by HLA-B7 were 
similar for both retroviral and liposome-mediated gene transfer, confirming that 
each method can provide appropriate and biologically active gene expression. 
This study also demonstrated that expression of a single foreign MHC gene by 
normal cells could induce a significant localized immune response. 
DIRECT GENE TRANSFER OF AUOGENEIC CLASS I 
MHC GENES INTO TUMORS 
The induction of a specific cell-mediated response generated by intravascular 
transfer of a foreign class I MHC gene suggested that this approach could be 
applied to the immunotherapy of malignancy. Previous studies using cell-me- 
diated gene transfer demonstrated that genetic modification of tumor cells can 
increase their immunogenicity and stimulate a specific antitumor response.2a38 
To determine whether a therapeutic immune response could be generated 
against preexisting macroscopic tumors, we introduced an allogeneic class I 
MHC gene by intratumoral injection of DNA liposome complexes or retroviral 
vectors. MHC alleles are highly polymorphic, and most of the variation between 
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alleles is concentrated in residues that comprise the peptide binding portion of 
the molecule.39 Consequently, transplanted tissue that expresses allogeneic MHC 
molecules is highly immunogenic, presumably due to the altered shape of the 
MHC in the peptide binding region. A high precursor frequency of CD8+ 
lymphocytes capable of reacting against allogeneic cells e x i ~ t s . ~ . ~ '  Therefore, 
introduction of an allogeneic class I MHC gene into tumors should stimulate a 
strong immune response locally. 
The murine class I MHC gene H-2K" was introduced into tumors in Pivo by 
direct intratumoral injection of a DNA liposome complex using DC-cholesterol 
liposomes. A weakly immunogenic murine tumor line CT26, a colon adeno- 
carcinoma with the H-2d haplotype, was inoculated subcutaneously in BALB/c 
mice. Approximately 14 days later, when tumors were 5-8 mm in diameter, the 
tumors were transduced with the H-2Ks gene. Lymphocytes harvested from 
these animals 14 days after gene transfer demonstrated lytic activity against 
CT26 targets expressing H-2K". More importantly, cytotoxic lymphocytes reac- 
tive against the parental nontransduced CT26 cells were present, demonstrating 
the generation of an immune response to other tumor antigens. Injection of a 
control gene P-galactosidase complexed with the liposomes did not induce cyto- 
lytic T cells. Cytolytic activity against both transduced and parental tumor cells 
could be blocked by antibody against CD8+ but not CD4+ lymphocytes. This 
immune response was not protective in this rapidly growing murine tumor 
model because the tumors were relatively large at the time of gene transfer and 
grew progressively during the generation of the antitumor response. Experi- 
ments using intratumoral transfer of the P-galactosidase gene suggest that the 
efficiency of gene transfer was approximately 1%. 
Significant attenuation of tumor growth and, in some cases, complete regres- 
sion of existing tumors were achieved following H-2Ks gene transfer when mice 
were presensitized to the H-2K' gene. Mice were preimmunized against H-2Ks 
by intraperitoneal injection of either irradiated tumor cells expressing H-2Ks or 
of splenic lymphocytes from an H-2s mouse strain. Two histologic types of 
tumors, the colon adenocarcinoma CT26 and the fibrosarcoma MCA 106 from 
two different mouse strains, BALB/c, and C57BL/6, respectively, responded to 
tumor transduction with the H-2K" gene. This study demonstrated that the 
immunologic response to H-2Ks was not strain specific or tumor specific. 
The antitumor response was mediated by T lymphocytes. The growth of 
CT26 or MCA 106 tumors in nude mice treated with the H-2K" gene was 
identical to that of P-galactosidase-treated mice or untreated controls. The im- 
mune response to H-2Ks gene transfer was abrogated by depletion of CD8+ T 
cells, but not by depletion of CD4+ cells. Direct gene transfer of the H-2Ks gene 
into the poorly immunogenic murine melanoma, B16BL6, in mice generated 
tumor-reactive lymphocytes in tumor-draining lymph nodes. When stimulated 
ex vivo with anti-CD3 mAb for two days followed by culture in low-dose IL-2 
(10 U/ml) for three days, these effector cells had no direct cytolytic activity 
against B 16BL6 targets. However, adoptive transfer of these lymphocytes to 
mice bearing B16BL6 lung metastases resulted in a marked decrease in lung 
metastases in comparison to a control gene." These studies demonstrate that 
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actively growing macroscopic tumors can be transduced with recombinant genes 
in vivo by intratumoral gene transfer using DNA liposome complexes. Moreover, 
an appropriate immunologic response can be generated against an allogeneic 
MHC protein expressed within actively growing tumors, and this strong im- 
mune response can stimulate a host immune response to weak tumor antigens. 
Appropriate augmentation of this antitumor immune response can mediate 
regression of preexisting tumors. 
IMMUNOTHERAPY OF HUMAN MALIGNANCY 
BY DIRECT GENE TRANSFER 
PRECLINICAL TOXICITY ANALYSIS 
To determine whether recombinant genes can be delivered safely in vivo using 
DNA liposome complexes, acute and long-term toxicity studies were performed 
in animal models. DC-cholesterol liposomes complexed with DNA were injected 
into mice intravenously or intratumorally, and the distribution of DNA was 
determined by PCR analysis of organs two to three weeks after gene transfer. 
The plasmid DNA was detected in heart and lung tissue in most cases and 
occasionally in kidney when mice received intravenous DNA liposome com- 
plexes. Intratumoral injection resulted in isolation of plasmid in tumor tissue and 
occasionally in heart, lung, and spleen. There were no histopathologic findings 
in the organs of any animals, including those containing plasmid DNA. In these 
instances, DNA was present at a very low level. Analysis of serum enzymes did 
not reveal evidence of liver, heart, or kidney dysfunction. Because of the finding 
of injected DNA in heart tissue, electrocardiography was performed during and 
after liposome injection. These electrocardiograms were all 
Expression of a foreign class I MHC gene on normal tissues could potentially 
induce autoimmunity. Mice that received the allogeneic MHC gene all generated 
a specific cytolytic T lymphocyte (CTL) response to the foreign gene product; 
however, there was no histopathologic or serologic evidence of organ t~xicity.~’ 
It is likely that immunologic tolerance to normal tissue prevented immune 
mediated damage from the low levels of allogeneic gene expression in these 
tissues following intratumoral gene transfer. Intravenous, intraperitoneal, or 
subcutaneous injection of the allogeneic MHC gene complexed with liposomes 
did not induce a detectable pathology. 
The potential for inadvertent modification of germ line tissue by recombinant 
gene is a concern for in vivo gene therapy. To address this question, 42 rabbits 
and pigs were treated with intravenous or intraarterial injection of DNA lipo- 
some complexes. Transfected DNA was never isolated from gonadal tissue by 
PCR, despite its presence in the transduced artery segments and occasionally in 
other organs.27 These studies demonstrate that direct gene transfer and expres- 
sion of recombinant genes, including a foreign MHC gene, do not induce 
generalized autoimmunity to normal tissue, or detectable gene transmission to 
germ cells. Direct gene transfer using DNA liposome complexes therefore ap- 
peared suitable for human gene therapy. 
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DIRECT GENE THERAPY IN HUMAN CANCER 
A phase I/II human gene therapy trial to provide immunotherapy for malig- 
nancy by direct intratumoral injection of an dogeneic MHC gene HLA-B7 
complexed with DC-Chol liposomes was approved by the Recombinant DNA 
Advisory Committee in January l%U.43 Patients with metastatic melanoma 
receive injections of the HLA-B7 gene into subcutaneous tumor nodules, with 
four study groups to receive escalating doses of the DNA liposome complex. The 
presence of transfected DNA, transcription of mRNA, and HLA-B7 protein 
expression are being analyzed after each injection in cells obtained from tumor 
biopsies. The presence of an immunologic response to HLA-B7 and autologous 
tumor cells are being studied using peripheral blood lymphocytes and tumor- 
infiltrating lymphocytes.44 The objectives of this ongoing clinical trial are: (1) to 
establish a safe and effective dose to introduce a recombinant gene, HLA-B7, 
into tumors by DNA liposome transfecdon; (2 )  to confirm expression of this 
class I MHC gene by tumor cells following direct gene transfer in vim; and (3) 
to analyze the immune response against this antigen and other tumor antigens. 
This protocol represents the first use of direct gene transfer into humans in 
mVo and is the first application of a nonviral vector-liposome-mediated gene 
transfer.& The stability of the DNA and liposomes coupled with the ease with 
which they can be reconstituted and administered to patients, provide the po- 
tential for such treatment to be provided in a generalized outpatient setting. 
Because most of the DNA is maintained extrachromosomally following lipo- 
some-mediated gene transfer, this approach would not provide permanent cor- 
rection for genetic disorders in proliferating cells. However, repeated treatments 
might provide sustained correction of genetic diseases at sufficient levels to 
ameliorate symptoms. Applications of gene therapy to many acquired disorders 
or to provide immunotherapy for malignancy would require only transient 
expression of recombinant genes. Most gene therapy models and human pro- 
tocols rely on modification of target cells m vim. This involves considerable effort 
and time, and the expense of large-scale dedicated tissue culture facilities. Addi- 
tionally, m vivo gene transfer would not be applicable in situations where target 
cells fail to grow in culture, as commonly occurs with many somatic cells and 
neoplastic cells. Direct gene transfer into patients avoids many of the disadvan- 
tages of ex pivo gene therapy and minimiim delays in the initiation of treatment. 
Anatomically localized delivery of DNA liposome complexes directly into the 
parenchyma of tissues or through intravascular catheters into the vascular bed 
can provide site-specific expression of recombinant genes in pivo. 
SUMMARY 
Direct gene transfer has been used to develop molecular genetic interventions 
for acquired diseases in several animal models. Through the use of intravascular 
catheters or anatomically localized injection of DNA liposome complexes, 
specific tissues can be transduced with recombinant genes. Several promising 
applications of this method for the study of vascular biology have been demon- 
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strated by direct gene transfer into arteries in Pivo. Delivery, via catheter, of genes 
that modulate the thrombogenic or proliferative properties of vascular cells may 
someday provide therapy for stenotic lesions of atherosclerosis or following 
angioplasty. Cancer is another acquired disorder in which direct gene transfer 
may improve the efficacy of treatment. Introduction of class I MHC or cytokine 
genes with antitumor or immunostimulatory effects have demonstrated promise 
in animal models. Direct transfer of an allogeneic class I MHC gene into tumors 
in vivo induces a CD8+ CTL response against weak antigens on poorly immun- 
ogenic tumors. The efficacy of this antitumor response can be augmented to 
induce regression of actively growing established tumors. Additional strategies, 
such as intratumoral delivery of combinations of multiple cytokine and MHC 
genes, may serve to improve the antitumor response. A clinical gene therapy 
protocol is underway to analyze the safety and efficacy of DNA liposome- 
mediated gene transfer in humans. Development of improved gene delivery 
systems and introduction of recombinant genes into visceral tumors by in- 
travascular catheter will extend the application of direct gene transfer to im- 
munotherapy of malignancies. These clinical trials of direct gene transfer will 
help to develop new treatment strategies for human diseases. 
REFERENCES 
1. PRICE, J., D. TURNER & C. CErKo. 1987. Lineage analysis in the vertebrate nervous 
system by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 84: 
156-160. 
2. NABEL, E. G., G. PLAUTZ & G. J.  NABEI.. 1990. Site-specific gene expression in vivo 
by direct gene transfer into the arterial wall. Science 249 1285-1288. 
3. CULVER, K. W., Z. RAM, S. WALLBRIDGE, H.  ISHII, E. H.  OI.DFIEI.D& R. M. 
BLAESE. 1992. In vivo gene transfer with retroviral vector-producer cells for treat- 
ment of experimental brain tumors. Science 256: 1550-1552. 
4. ROSENFELD,M. A., W. SIEGFRIED, K. YOSHIMURA, K. YONEYAMA,M. FUKAYAMA, L. 
E. STIER, P. K. PAAKKO, P. GILARDI, L. D. STRATFORD-PERRICAUDET, M. PER- 
RicAuDmet al. 1991. Adenovirus-mediated transfer of a recombinant alpha 1- 
antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434. 
THAL, W. DALEMANS, M. FUKAYAMA, J. BARGON, L. E. STIER, L. STRATFORD- 
PERRICAUDETC~ al. 1992. In vivo transfer of the human cystic fibrosis trans- 
membrane conductance regulator gene to the airway epithelium. Cell 68: 
6. JAFFE, H .  A., C. DANEL, G. LONCENECKER, M. METZGER, Y. SETOCUCHI, M. A. 
ROSENFELD, T. W. GANT, S. S. THORCEIRSSON, L. D. STRATFORD-PERRICAUDET, 
M. PERRICAUDET, A. PAVIRANI, J. P. LECOCQ & R. G. CRYSTAL. 1992. Adenovi- 
rus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet. 
7. SAMULSKI, R. J., X. ZHU,  X. XIAO, J. D. BROOK, D. E. HOUSMAN, .EPSTEIN & L. 
A. HUNTER. 1991. Targeted integration of adeno-associated virus (AAV) into 
human chromosome 19 [ ublished erratum appears in EMBO J. 1992. Mar; 
l l (3) :  12281. EMBO J. I!: 3941-3950. 
8. PALELLA, T. D., L. J. SILVERMAN, C. T. SCHROLL, F. L. HOMA, M. LEVINE & W. N. 
KELLEY. 1988. Her simplex virus-mediated human hypoxanthine-guanine 
phosphoribosyltransrw gene transfer into neuronal cells. Mol. Cell. Biol. 8: 
457-460. 
5. ROSENFELD, M. A., K. YOSHIMURA, B. C. TRAPNELL, K. YONEYAMA, E. R. ROSEN- 
143-155. 
1: 372-378. 
152 ANNALS NEW YORK ACADEMY OF SCIENCES 
9. CHIOCCA, E. A., B. B. CHOI, W. Z. CAI, N. A. DELUCE, P. A. SCHAFFER, M. 
DEFIGLIA, X. 0. BREAKFIELD & R. L. MARTUZA. 1990. Transfer and expression of 
the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New 
Biol. 2: 739-746. 
10. BREAKEFIELD, X. 0. & N. A. DELUCA. 1991. Herpes simplex virus for gene delivery 
to neurons. New Biol. 3: 203-218. 
11. WOLFF, J. A., R. W. MALONE, P. WILLIAMS, G. CHONG, G. ASCADI, A. JANI  & P. 
FELGNER. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 
12. LIN, H., M. S. PARMACEK, G. MORLE, S. BOLLINC & J. M. LEIDEN. 1990. Expression 
of recombinant enes in myocardium in vivo after direct injection of DNA. Circula- 
tion 82: 221723221. 
13. ACSADI, G., S. S. JIAO, A. JANI, D. DUKE, P. WILLIAMS, W. CHONC & J. A. WOLFF. 
1991. Direct gene transfer and expression into rat heart in vivo. New Biol. 3: 
14. VILE, R. G. & I. R. HART. 1993. In Pitro and in PiPo Targeting of gene expression 
to melanoma cells. Cancer Res. 53: 962-967. 
15. BRIGHAM, K. L., B. MEYRICK, B. CHRISTMAN, M. MAGNUSON, G. KING & L. C. 
BERRY. 1989. In vivo transfection of murine lungs with a functioning prokaryotic 
gene using a liposome vehicle. Am. J. Med. Sci. 298: 278-281. 
16. HOLT, C. I., N. GARLICK & E. CORNEL. 1990. Lipofection of cDNAs in the em- 
bryonic vertebrate central nervous system. Neuron 4 203-214. 
17. PLAUTZ, G. E., Z. Y. YANC, B. Wu, X. GAO, L. HUANC& G. J. NABEL. 1993. 
Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. 
Acad. Sci. USA 90: 46454649. 
18. NABEL, E. G., Z. YANG, G. PLAUTZ, R. FOROUGH, X. ZHAN, C. C. HAUDENSCHIID, 
T. MACIAG & G. J. NABEL. 1993. Recombinant fibroblast growth factor-1 pro- 
motes intimal hyperplasia and angiogenesis in arteries in PiPo. Nature 362: 844- 
846. 
19. NABEL, E. G., Z. YANG, S. LIPTAY, H. SAN D. GORDON, C. C. HAUDENSCHII.D & G. 
J. NABEL. 1993. Recombinant latelet-derived growth factor B gene ex ression in 
porcine arteries induces intirnal~yperplasia in vivo. J. Clin. Invest. 91: 1122-1829. 
20. FELGNER, P. L. & G. M. RINCOLD. 1989. Cationic liposome-mediated transfection. 
Nature 337: 387-388. 
21. FELGNER, P. L., M. HOLM & H. CHAN. 1989. Cationic liposome mediated trans- 
fection. Proc. West. Pharmacol. Soc. 32: 115-121. 
22. FELGNER, P. L., T. R. GADEK, M. HOLM, R. ROMAN, H. W. CHAN, M. WENZ, J. P. 
NORTHROP, G. M. RINGOLD& M. DANIELSEN. 1987. Lipofeaion: A high1 




23. NABEL, E. G., G. PLAUTZ & G. J. NABEL. 1992. Transduction of a foreign histo- 
compatibility ene into the arterial wall induces vasculitis. Proc. Natl. Acad. Sci. 
USA 89: 5159-5161. 
24. LIM, C. S., G. D. CHAPMAN, R. S. GAMMON, J. B. MUHLESTEIN, R. P. BAUMAN, R.
S. STACK & J. L. SWAIN. 1991. Direct in vivo gene transfer into the coronary and 
peripheral vasculatures of the intact dog. Circulation 83: 2007-201 1. 
25. GAO, X. & L. HUANG. 1991. A novel cationic liposome reagent for efficient trans- 
fection of mammalian cells. Biochem. Biophys. Res. Commun. 179: 280-285. 
26. STEWART, M. J., G. E. PLAUTZ, L. DELBUONO, Z. Y. YANG, L. Xu, X. GAO, L. 
HUANG, E. G. NABEL& G. J. NABEL. 1992. Gene transfer in vivo with DNA- 
liposome complexes: Safety and acute toxicity in mice. Hum. Gene Ther. 3: 
27. NABEL, E. G., D. GORDON, Z.-Y. XANC, L. Xu, H. SAN, G. E. PLAUTZ, X. GAO, L. 
HUANC & G. J. NABEL. 1992. Gene transfer in vivo with DNA-liposome com- 
plexes: Lack of autoimmunity and gonadal localization. Hum. Gene Ther. 3: 
649-656. 
28. FEARON, E. R., D. M. PARDOLI., T. ITAYA, P. GOLUMBEK, H. I. LEVITSKY, J. W. 
267-275. 
PLAUTZ et al.: DIRECT GENE TRANSFER 153 
SIMONS, H. KARASUYAMA, B. VOGELSTEIN & P. FROST. 1990. Interleukin-2 prod- 
uction by tumor cells bypasses T helper function in the generation of an antitumor 
response. Cell 60: 3 9 7 4 3 .  
29. GANSBACHER, B., K. ZIER, B. DANIELS, K. CRONIN, R. BANNERJI & E. GILBOA. 
1990. Interleukin 2 gene transfer into tumor cells abro ates tumorigenicity and 
induces protective immunity. J. Ex , Med. 172: 1217-f224. 
30. TEPPER, . I., P. K. PATTENGALE & 1. LEDER. 1989. Murine interleukin-4 displays 
potent antitumor activity in vim. Cell 57: 503-512. 
31. LI, W., T. DIAMANTSTEIN & T. BLANKENSTEIN. 1990. Lack of tumori enicity of 
interleukin 4 autocrine growin cells seems related to the anti-tumor tnction of 
interleukin 4. Mol. Immunol. g7: 1331-1337. 
32. GOLUMBEK, P. T., A. J. LAZENBY, H. I. LEVITSKY, L. M. JAFFEE, H. KARASUYAMA, 
M. BAKER& D. M. PARDOLL. 1991. Treatment of established renal cancer by 
tumor cells engineered to secrete interleukin-4. Science 254 713-716. 
33. GANSBACHER, B., R. BANNERJI, B. DANIELS, K. ZIER, K. CRONIN & E. GII.BOA. 
1990. Retroviral vector-mediated y-interferon gene transfer into tumor cells en 
erates potent and long lasting antitumor immunity. Cancer Res. 50: 7820-7i25: 
34. CHEN, L., S. ASHE, W. A. BRADY, I. HELLSTROM, K. E. HELLSTROM, J. A. LEDBET- 
TER, P. MCGOWAN & P. S. LINSLEY. 1992. &stimulation of antitumor immunity 
by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 
35. TOWNSEND, S. & J. P. ALLISON. 1993. Tumor rejection after direct costimulation of 
CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370. 
36. BLANKENSTEIN,TH., Z. QIN, K. UBERLA, W. MWLLER, H. ROSEN, H.-D. VOI.K &T.  
DIAMANSTEIN. 1991. Tumor suppression after tumor cell-targeted tumor necrosis 
factor a gene transfer. J. Ex 
37. TENG, M. N., B. H. PARK, R'. K. KOEPPEN, K. J. TRACEY, B. M. FENDLY & H. 
SCHREIBER. 1991. Long-term inhibition oftumor growth by tumor necrosis factor 
in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. USA 88: 
3535-3539. 
38. ASHER,A. L., J. J. MULE, A. KASID, N. P. RESTIFO, J. C. SALO, C. M. REICHERT, G. 
JAFFE, B. FENDLY, M. KRIECLER & S. A. ROSENBERC. 1991. Murine tumor cells 
transduced with the gene for tumor necrosis factor-a. J. Immunol. 1%: 3227- 
3234. 
R. D. SALTER, A. M. WAN & P. D. ENNIS. 1988. Nature of polymor hism in 
40. SKINNER, M. A. & J. MARBROOK. 1976. An estimation of the frequency of recursor 
cells which enerate cytotoxic lym hocytes. J. Exp. Med. 143: 1562-15)67. 
41. LINDAHL, K. E. & D. B. WiI.soN. 1877. Histocom atibility antigen-activated cyto- 
in vitro. J. gz. Med. 145: 500-522. 
42. WAHI., W. L., E. PI.AUTZ, B. A. Fox, G. J. NABEI., S. SHU &A. E. CHANC. 1992. 
Generation of therapeutic 1 phocytes after in vivo transfection of tumor with a 
43. NAREL, G. J., A. CHANG, E. G. NAREL, G. PLAUTZ, B. A. Fox, L. HUANC & S. SHU. 
1992. Clinical rotocol. Immunotherapy of malignancy by in vivo gene transfer 
into tumors. dm. Gene Ther. 3: 399410. 
44. NABEL,G. J , E. G. NABEI., Z. YANG, B. Fox,G. P L A U T Z , ~ .  GAO, L. HUANG, S. SHU, 
D. GORDON & A. E. CHANC. 1993. Direct gene transfer with DNA lipsome 
complexes in humans: Expression, lack of toxicity and therapeutic potential in 
melanoma. Proc. Natl. Acad. Sci. USA 90: 10759-10763. 
71: 1093-1 102. 
Med. 173: 1047-1052. 
39. PARHAM, P., C. E. LOMEN, D. A. LAWLOR, J. P. WAYS, N. HOLMES, H. L. COPPIN, 
HLA-A, -B, and -C molecules. Proc. Natl. Acad. Sci. USA 85: 4005 4.l 09. 
toxic T lym hocytes I. Estimates of the absolute P requency of luller cells generated 
gene encoding dogeneic c r" ass I MHC antigen. Surg. Forum 63: 476478. 
